Alzheimers Disease Research Centers (P30 Clinical Trial Not Allowed) | RFA AG 21 019

Opportunity Information: Apply for RFA AG 21 019

The National Institutes of Health (NIH), through the National Institute on Aging (NIA), issued this discretionary grant opportunity (Funding Opportunity Number RFA-AG-21-019) to support Alzheimer’s Disease Research Centers (ADRCs) under the P30 center grant mechanism, with clinical trials not allowed under this announcement. ADRCs are meant to function as major, multidisciplinary hubs for research on Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). The overall purpose is to strengthen discovery about disease causes and progression, while also improving real-world approaches to prevention, diagnosis, care, and therapy. A central expectation is that these centers do more than run isolated projects: they build shared infrastructure, generate and distribute common resources, and coordinate closely with other NIH-funded programs and investigators to accelerate dementia-relevant research.

This FOA emphasizes the ADRC role as a collaborative, resource-building enterprise. In practice, that means creating and maintaining shared cores, data and specimen resources, and other research-enabling capabilities that can support multiple investigators and studies focused on AD/ADRD. The announcement highlights that NIA-designated ADRCs contribute substantially to shared resources for the broader research community, positioning the centers as regional or national anchors for dementia research capacity, standardized approaches, and coordinated scientific effort. Because it is labeled “Clinical Trial Not Allowed,” applications must be structured so that proposed activities do not include NIH-defined clinical trials, even if the work involves human participants in observational or non-interventional ways consistent with NIH policy for non-trial research.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education, since those fall under their own category); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

Foreign participation is limited in a specific way. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply as the applicant organization. However, “foreign components” are allowed as defined by the NIH Grants Policy Statement, meaning a U.S. applicant can include certain foreign elements in the project when justified and compliant with NIH rules, even though a foreign institution cannot be the primary applicant.

Key administrative details from the source listing include the activity category of Health and the CFDA number 93.866. The opportunity was created on 2020-03-11, with an original closing date of 2020-09-15. The listed award ceiling is $2,000,000. The source record does not specify the number of expected awards. Overall, the FOA is aimed at sustaining or building high-impact Alzheimer’s research centers that serve as shared-resource engines and coordination points for the AD/ADRD scientific community, while staying within the non-clinical-trial scope required by the announcement.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alzheimers Disease Research Centers (P30 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
• This funding opportunity was created on 2020-03-11.
• Applicants must submit their applications by 2020-09-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AG 21 019

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: